Literature DB >> 23124138

The tyrosine phosphatase TC48 interacts with and inactivates the oncogenic fusion protein BCR-Abl but not cellular Abl.

Aninda Mitra1, Kotagiri Sasikumar, B V V Parthasaradhi, Vegesna Radha.   

Abstract

The chimeric oncoprotein BCR-Abl exhibits deregulated protein tyrosine kinase activity and is responsible for the pathogenesis of certain human leukemias, such as chronic myelogenous leukemia. The activities of cellular Abl (c-Abl) and BCR-Abl are stringently regulated and the cellular mechanisms involved in their inactivation are poorly understood. Protein tyrosine phosphatases can negatively regulate Abl mediated signaling by dephosphorylating the kinase and/or its substrates. This study investigated the ability of the intracellular T cell protein tyrosine phosphatase (TCPTP/PTPN2) to dephosphorylate and regulate the functions of BCR-Abl and c-Abl. TCPTP is expressed as two alternately spliced isoforms - TC48 and TC45, which differ in their C-termini and localize to the cytoplasm and nucleus respectively. We show that TC48 dephosphorylates BCR-Abl but not c-Abl and inhibits its activity towards its substrate, CrkII. Y1127 and Y1294 residues whose phosphorylation corresponds with BCR-Abl activation status were the primary sites targeted by TC48. Co-localization and immunoprecipitation experiments showed that TC48 interacted with BCR-Abl but not with c-Abl, and BCR domain was sufficient for interaction. TC48 expression resulted in the stabilization of Bcr-Abl protein dependent on its phosphatase activity. Inactivation of cellular TC48 in K562 cells by stable expression of a dominant negative catalytically inactive mutant TC48, enhanced proliferation. TC48 expressing K562 clones showed reduced proliferation and enhanced sensitivity to STI571 compared to control clones suggesting that TC48 can repress the growth of CML cells. This study identifies a novel cellular regulator that specifically inhibits the activity of oncogenic BCR-Abl but not that of the cellular Abl kinase.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23124138     DOI: 10.1016/j.bbadis.2012.10.014

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  3 in total

1.  Elevated PTPN2 expression is associated with inferior molecular response in de-novo chronic myeloid leukaemia patients.

Authors:  C H Kok; T Leclercq; D B Watkins; V Saunders; J Wang; T P Hughes; D L White
Journal:  Leukemia       Date:  2013-11-06       Impact factor: 11.528

2.  PTPRG and PTPRC modulate nilotinib response in chronic myeloid leukemia cells.

Authors:  Julia Drube; Thomas Ernst; Markus Pfirrmann; Benadict Vincent Albert; Sebastian Drube; Daniela Reich; Anne Kresinsky; Kathrin Halfter; Claudio Sorio; Christian Fabisch; Andreas Hochhaus; Frank-D Böhmer
Journal:  Oncotarget       Date:  2018-01-15

Review 3.  Current Views on the Interplay between Tyrosine Kinases and Phosphatases in Chronic Myeloid Leukemia.

Authors:  Christian Boni; Claudio Sorio
Journal:  Cancers (Basel)       Date:  2021-05-12       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.